Breaking News, Collaborations & Alliances

EU Selects SK bioscience, IDT Biologika, Vaxxas for Next-Gen Flu Vaccine Development

The three-party consortium will use Vaxxas’ needle-free technology to develop a seasonal and pandemic flu vaccine.

Author Image

By: Patrick Lavery

Content Marketing Editor

SK bioscience, IDT Biologika, and Vaxxas will collaborate on a next-generation influenza vaccine development initiative. The European Health and Digital Executive Agency (HaDEA) manages the initiative for the European Commission’s Health Preparedness and Response Authority (HERA). Roles of SK, IDT, Vaxxas SK bioscience, which acquired IDT Biologika in October 2024, will supply drug substance that leverages its proprietary cell culture technology. Meanwhile, Vaxxas will lend its hi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters